tetano
Editor, Senior Moderator
Mucosal Immunol
. 2024 Jan 10:S1933-0219(24)00002-3.
doi: 10.1016/j.mucimm.2024.01.002. Online ahead of print. A bacterial vesicle-based pneumococcal vaccine against influenza-mediated secondary Streptococcus pneumoniae pulmonary infection
Saugata Majumder[SUP] 1 [/SUP], Peng Li[SUP] 1 [/SUP], Shreya Das[SUP] 1 [/SUP], Tanvir Noor Nafiz[SUP] 1 [/SUP], Sudeep Kumar[SUP] 1 [/SUP], Guangchun Bai[SUP] 1 [/SUP], Hazel Dellario[SUP] 2 [/SUP], Haixin Sui[SUP] 2 [/SUP], Ziqiang Guan[SUP] 3 [/SUP], Roy Curtiss 3rd[SUP] 4 [/SUP], Yoichi Furuya[SUP] 5 [/SUP], Wei Sun[SUP] 6 [/SUP]
Affiliations
Streptococcus pneumoniae (Spn) is a common pathogen causing a secondary bacterial infection following influenza which leads to severe morbidity and mortality during seasonal and pandemic influenza. Therefore, there is an urgent need to develop bacterial vaccines that prevent severe post-influenza bacterial pneumonia. Here, an improved Yersinia pseudotuberculosis strain (designated as YptbS46) possessing an Asd[SUP]+[/SUP] plasmid pSMV92 could synthesize high amounts of the Spn pneumococcal surface protein A (PspA) antigen and monophosphoryl lipid A as an adjuvant. The recombinant strain produced outer membrane vesicles (OMVs) enclosing a high amount of PspA protein (designated as OMV-PspA). A prime-boost intramuscular immunization with OMV-PspA induced both memory adaptive and innate immune responses in vaccinated mice, reduced the viral and bacterial burden, and provided complete protection against influenza-mediated secondary Spn infection. Also, the OMV-PspA immunization afforded significant cross-protection against the secondary Spn A66.1 infection and long-term protection against the secondary Spn D39 challenge. Our study implies that an OMV vaccine delivering Spn antigens can be a new promising pneumococcal vaccine candidate.
Keywords: Outer membrane vesicles; S. pneumoniae; co-infection; influenza virus; vaccine.
. 2024 Jan 10:S1933-0219(24)00002-3.
doi: 10.1016/j.mucimm.2024.01.002. Online ahead of print. A bacterial vesicle-based pneumococcal vaccine against influenza-mediated secondary Streptococcus pneumoniae pulmonary infection
Saugata Majumder[SUP] 1 [/SUP], Peng Li[SUP] 1 [/SUP], Shreya Das[SUP] 1 [/SUP], Tanvir Noor Nafiz[SUP] 1 [/SUP], Sudeep Kumar[SUP] 1 [/SUP], Guangchun Bai[SUP] 1 [/SUP], Hazel Dellario[SUP] 2 [/SUP], Haixin Sui[SUP] 2 [/SUP], Ziqiang Guan[SUP] 3 [/SUP], Roy Curtiss 3rd[SUP] 4 [/SUP], Yoichi Furuya[SUP] 5 [/SUP], Wei Sun[SUP] 6 [/SUP]
Affiliations
- PMID: 38215909
- DOI: 10.1016/j.mucimm.2024.01.002
Streptococcus pneumoniae (Spn) is a common pathogen causing a secondary bacterial infection following influenza which leads to severe morbidity and mortality during seasonal and pandemic influenza. Therefore, there is an urgent need to develop bacterial vaccines that prevent severe post-influenza bacterial pneumonia. Here, an improved Yersinia pseudotuberculosis strain (designated as YptbS46) possessing an Asd[SUP]+[/SUP] plasmid pSMV92 could synthesize high amounts of the Spn pneumococcal surface protein A (PspA) antigen and monophosphoryl lipid A as an adjuvant. The recombinant strain produced outer membrane vesicles (OMVs) enclosing a high amount of PspA protein (designated as OMV-PspA). A prime-boost intramuscular immunization with OMV-PspA induced both memory adaptive and innate immune responses in vaccinated mice, reduced the viral and bacterial burden, and provided complete protection against influenza-mediated secondary Spn infection. Also, the OMV-PspA immunization afforded significant cross-protection against the secondary Spn A66.1 infection and long-term protection against the secondary Spn D39 challenge. Our study implies that an OMV vaccine delivering Spn antigens can be a new promising pneumococcal vaccine candidate.
Keywords: Outer membrane vesicles; S. pneumoniae; co-infection; influenza virus; vaccine.